$1.30
0.043.17%
Last update: Nov 10, 6:02 AM
MaxCyte Inc
MXCTNASDAQ
MaxCyte fell 11.6% from $1.47 to $1.30, behind the S&P 500's +10.5%. Its worst day was Dec 3 (−13.6%), and its low came Mar 30 at $0.68.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.12 missed the $-0.10 estimate on $6.8M revenue (est. $8.9M); FY revenue guidance of $29.3M–$32.5M against the $37.0M consensus.
−4.4% · S&P 500 −1.7%
Story events cover the past 12 months · Times ET
MaxCyte closed at its highest level of the year, 19.7% above where the year started.
+0.6% · S&P 500 +0.5%
EPS of $-0.09 missed the $-0.08 estimate on $7.3M revenue (est. $9.2M); FY revenue guidance of $30.0M–$32.0M against the $38.1M consensus.
−6.8% · S&P 500 +0.6%
EPS of $-0.04 beat the $-0.09 estimate on $9.7M revenue (est. $7.3M); FY revenue guidance of $30.0M–$32.0M against the $30.8M consensus.
+24.1% · S&P 500 +0.6%
EPS of $-0.08 beat the $-0.10 estimate on $7.3M revenue (est. $6.5M); FY revenue guidance of $30.0M–$32.0M against the $31.1M consensus.
+9.4% · S&P 500 +0.7%
MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
+29.6%, the year's best day · S&P 500 −1.1%
Where it ended: a close of $1.30 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $-0.08, revenue est. $7.4M).
Nothing in the past 12 months.
All MXCT dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MXCT and SPY from Benzinga historical bars. Not investment advice.
